You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

Covid-19 - Resource center

Medizinische Fachkräfte finden Hilfe und Orientierung, wie sie unsere Angebote zur Behandlung Ihrer Patienten nutzen können. Zusätzlich erhalten Sie weitere praktische Informationen und Ratschläge.

Erfahren Sie mehr

Apllikon webinar Rapid process development for production of SARS-CoV-2 spike proteins 2020-09-30

Rapid process development for production of SARS-CoV-2 spike proteins

Webinar timings:
9:00AM - 10:00AM CET
4.00PM - 5:00PM CET
7:00PM - 8:00PM CET

online September 30, 2020

Presented by: Jort Altenburg , Bioprocess Engineering, Wageningen University

To control the pandemic SARS-CoV-2 outbreak, rapid development of a COVID-19 vaccine is needed as well as serological tests to determine whether or not someone has contracted the virus and has built up immunity. The baculovirus-insect cell expression system can be used to produce the SARS-CoV-2 spike protein for vaccine and serological test applications. To produce sufficient amounts of spike protein in a relatively short period of time, rapid screening for optimal process conditions is of utmost importance. Within this development of the Laboratory of Virology and the Bioprocess Engineering Group of Wageningen University, the Applikon micro-Matrix is used to screen different conditions for optimal cell growth and protein production in Sf9 cells. The micro-Matrix system allows for simultaneously performing 24 cultivations in a deep well plate with control of DO, pH and temperature. Therefore screening for optimal pH value can be done in a single experiment. Optimal conditions are also checked in the Applikon 500 mL miniBio (autoclavable bioreactor) and 500 mL AppliFlex ST (single-use bioreactor) and will eventually be scaled up to a 20 liter bioreactor, producing sufficient material for pre-clinical animal trials and serological testing. 

Register and learn more about:

  • the scale up process for protein production
  • the screening of optimium process conditions
  • acceleration of you process development 

Target audience

  • Anyone interested in research and development of vaccines, more specific in COVID-19 vaccine candidate
  • Scientists
  • Lab managers


Datum: September 30, 2020
Stadt: online
Veranstaltungsort: online event

Website der Veranstaltung anzeigen